Notice of Change to Application Review Information in PAR-18-802, "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)"

Notice Number: NOT-CA-18-104

Key Dates
Release Date: August 31, 2018

Related Announcements
PAR-18-802

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the Application Review Information in Funding Opportunity Announcement (FOA) PAR-18-802, "Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)".

The following section of the FOA ?has been corrected:

Section V. Application Review Information, 2. Review and Selection Process

Currently reads:

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

Should correctly read (in italics):

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by Center for Scientific Review (CSR), in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

All other aspects of this Funding Opportunity Announcement remain unchanged.

Inquiries

Please direct all inquiries to:

Ming Zhao, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5225 
Email: zhaoming3@mail.nih.gov